Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 40.21M | 32.00M | 14.36M | 18.88M | 18.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.21M | 32.00M | 14.36M | 18.88M | 18.80M |
| Cost of Revenue | 12.99M | 14.70M | 8.24M | 10.68M | 10.33M |
| Gross Profit | 27.23M | 17.30M | 6.12M | 8.20M | 8.47M |
| SG&A Expenses | 3.46M | 2.09M | 2.80M | 2.33M | 2.02M |
| Depreciation & Amortization | 394.90K | 409.90K | 432.50K | 420.30K | 425.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.51M | 19.24M | 13.27M | 15.40M | 14.94M |
| Operating Income | 21.70M | 12.76M | 1.10M | 3.48M | 3.86M |
| Income Before Tax | -564.20K | 19.27M | -10.65M | -9.52M | 847.80K |
| Income Tax Expenses | 5.32M | 2.27M | 239.20K | 1.52M | 232.00K |
| Earnings from Continuing Operations | -5.88M | 17.00M | -10.89M | -11.04M | 615.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.88M | 17.00M | -10.89M | -11.04M | 615.80K |
| EBIT | 21.70M | 12.76M | 1.10M | 3.48M | 3.86M |
| EBITDA | 22.09M | 13.17M | 1.53M | 3.91M | 4.29M |
| EPS Basic | -0.01 | 0.02 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.01 | 0.02 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 1.07B | 1.07B | 1.07B | 1.07B | 1.07B |
| Average Diluted Shares Outstanding | 1.07B | 1.07B | 1.07B | 1.07B | 1.08B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |